ACB:CA:TSX-Aurora Cannabis Inc (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

CAD 6.39

Change

-0.29 (-4.34)%

Market Cap

CAD 0.36B

Volume

0.28M

Analyst Target

CAD 16.10
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers medical and consumer cannabis products; supplies propagated vegetables and ornamental plants; and distributes and sells hemp-derived cannabidiol (CBD) products. The company also cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, dried flowers, vapes, dried milled strains, edibles, concentrates, and strain specific cannabis oils and extracts; and provides patient counseling and outreach services. Its adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. The company was founded in 2013 and is headquartered in Edmonton, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
BHC:CA Bausch Health Companies Inc

-0.01 (-0.09%)

CAD 3.94B
TLRY:CA Tilray Inc

-0.12 (-5.69%)

CAD 1.89B
CURA:CA Curaleaf Holdings Inc.

-0.17 (-7.42%)

CAD 1.61B
CRON:CA Cronos Group Inc

+0.01 (+0.35%)

CAD 1.07B
DHT-UN:CA DRI Healthcare Trust

-0.33 (-2.64%)

CAD 0.75B
WEED:CA Canopy Growth Corp

-0.28 (-6.78%)

CAD 0.60B
AOV:CA Amotiv Limited

+0.01 (+0.18%)

CAD 0.58B
GUD:CA Knight Therapeutics Inc.

+0.01 (+0.18%)

CAD 0.58B
DHT-U:CA DRI Healthcare Trust

+0.25 (+3.03%)

CAD 0.54B
CPH:CA Cipher Pharmaceuticals Inc

+0.08 (+0.55%)

CAD 0.38B

ETFs Containing ACB:CA

CNDA Concord Acquisition Corp .. 0.00 % 0.70 %

N/A

USD 0.10B
AUGA:LSE UBS (Irl) ETF plc - MSCI .. 0.00 % 0.00 %

+2.50 (+0.00%)

N/A
AUAD:LSE UBS (Irl) ETF plc - MSCI .. 0.00 % 0.00 %

+12.25 (+0.00%)

N/A
HMXJ:LSE HSBC ETFs Public Limited .. 0.00 % 0.00 %

+7.50 (+0.00%)

N/A
IAUS:LSE iShares MSCI Australia UC.. 0.00 % 0.00 %

-0.23 (0.00%)

N/A
DX2S:F Xtrackers - S&P ASX 200 U.. 0.00 % 0.00 %

+0.39 (+0.00%)

N/A
DXS6:F Xtrackers - MSCI Pacific .. 0.00 % 0.00 %

N/A

N/A
SXR1:F iShares Core MSCI Pac ex-.. 0.00 % 0.00 %

N/A

USD 2.82B
UIMD:F UBS ETF SICAV - MSCI Paci.. 0.00 % 0.00 %

+0.31 (+0.00%)

USD 0.06B
VGEJ:F Vanguard Funds Public Lim.. 0.00 % 0.00 %

N/A

USD 1.36B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.58% 68% D+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.58% 68% D+ 90% A-
Trailing 12 Months  
Capital Gain 3.06% 67% D+ 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.06% 67% D+ 19% F
Trailing 5 Years  
Capital Gain -97.52% 29% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.52% 29% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain 361.23% 100% F 99% N/A
Dividend Return 361.23% 100% F 99% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 2,390.49% 5% F 1% F
Risk Adjusted Return 15.11% 82% B 30% F
Market Capitalization 0.36B 57% F 54% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector